Biotechnology Value Trading Fund OS LP
CIK 1660683 · last filed 2025-05-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$442.17M
Companies
14
Total Filings
20
Lifetime Open-Market Net
-$1.22B
Filer Profile
Reported Address
P.O. BOX 309 UGLAND HOUSEGRAND CAYMAN, E9 KY1-1104
Phone
(415) 525-8890
State of Incorporation
Cayman Islands
Related Filers
BIOTECHNOLOGY VALUE FUND II LP — 237 joint filings, latest 2026-07-16
BIOTECHNOLOGY VALUE FUND L P — 237 joint filings, latest 2026-07-16
BVF INC/IL — 237 joint filings, latest 2026-07-16
BVF PARTNERS L P/IL — 237 joint filings, latest 2026-07-16
BVF Partners OS Ltd. — 237 joint filings, latest 2026-07-16
MARK N LAMPERT — 237 joint filings, latest 2026-07-16
BVF GP HOLDINGS LLC — 155 joint filings, latest 2026-07-16
BVF I GP LLC — 155 joint filings, latest 2026-07-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XOMA Royalty Corp (XOMAP) Delisted | 1,322,758 | $24.98 | $33.04M | -$106.43M | 1 | 2025-05-20 | |
| KYMR | Director | 1,888,351 | $114.96 | $217.08M | $0 | 1 | 2023-06-20 |
| GPCR | 0 | $38.66 | $0 | $0 | 1 | 2023-05-12 | |
| Repare Therapeutics Inc. (RPTX) Delisted | 3,299,906 | $2.65 | $8.74M | $18.99M | 1 | 2022-06-15 | |
| CGEM | 364,161 | $20.59 | $7.50M | $82.65M | 1 | 2022-06-03 | |
| CTI BIOPHARMA CORP (CTIC) Delisted | 3,102,435 | $9.09 | $28.20M | $50.00M | 2 | 2021-04-05 | |
| Merus N.V. (MRUS) Delisted | 3,513,335 | $90.00 | $316.20M | $209.06M | 1 | 2021-01-25 | |
| CYTK | 2,777,320 | $73.77 | $204.88M | $0 | 1 | 2020-11-20 | |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 670,695 | $38.00 | $25.49M | -$1.49B | 2 | 2020-11-13 | |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 32,062 | $15.70 | $503.4K | $25.65M | 1 | 2020-11-03 | |
| XOMA Royalty Corp (XOMA) Delisted | 2,022,816 | $40.17 | $81.26M | $4.31M | 3 | 2020-09-10 | |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 952,859 | $8.37 | $7.98M | -$28.94M | 1 | 2019-06-12 | |
| XENE | 216,694 | $58.65 | $12.71M | $0 | 1 | 2018-03-29 | |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 2,968,487 | $0.04 | $132.7K | $14.06M | 1 | 2017-10-05 |
Recent Filings · Page 2 of 2
20 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-20 | CYTK | Other (J) | — | $0 | EDGAR |
| 2020-11-13 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Sell (S) | −73,933,400 | -$1.49B | EDGAR |
| 2020-11-03 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +9,326,120 | $25.65M | EDGAR |
| 2020-09-10 | XOMA Royalty Corp (XOMA) Delisted | Buy (P) | +77,370 | $1.45M | EDGAR |
| 2020-04-17 | XOMA Royalty Corp (XOMA) Delisted | Conv (C) | +12,527,720 | $162.86M | EDGAR |
| 2019-10-31 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +205,198 | $796.7K | EDGAR |
| 2019-06-12 | CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | Sell (S) | −2,704,023 | -$28.94M | EDGAR |
| 2019-05-14 | XOMA Royalty Corp (XOMA) Delisted | Buy (P) | +195,391 | $2.86M | EDGAR |
| 2018-03-29 | XENE | Other (J) | −17,059,000 | $0 | EDGAR |
| 2017-10-05 | INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | Buy (P) | +11,200,322 | $14.06M | EDGAR |
Showing 11–20 of 20
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.